|
Malignant neoplasm of lung
|
0.300 |
Biomarker
|
disease |
CTD_human |
Identification of DOK genes as lung tumor suppressors.
|
20139980 |
2010 |
|
ovarian neoplasm
|
0.300 |
Therapeutic
|
disease |
CTD_human |
Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer.
|
21856257 |
2011 |
|
Malignant neoplasm of ovary
|
0.300 |
Therapeutic
|
disease |
CTD_human |
Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer.
|
21856257 |
2011 |
|
leukemia
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
To assess the so far unknown role of DOK1 in colorectal cancer (CRC), we generated DOK1 mutants which mimic the domain structure and subcellular distribution of DOK1 protein variants in leukemia patients.
|
27428427 |
2016 |
|
leukemia
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
The data in this report show that both the DOK1 and the DOK2 adaptor proteins are constitutively expressed in the myelomonoblastic leukemia cell line, HL-60, and that expression of both proteins is induced by the chemotherapeutic differentiation causing agents, all-trans retinoic acid (atRA) and 1,25-dihydroxyvitamin D3 (VD3).
|
16823827 |
2006 |
|
leukemia
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Survival analyses showed that low-expressed DOK1/2 were associated with markedly shorter overall survival and leukemia free survival in both whole-cohort AML and non-M3 AML patients.
|
29150948 |
2018 |
|
leukemia
|
0.050 |
Biomarker
|
disease |
BEFREE |
Among the genes identified, one of particular interest was DOK1, or downstream of tyrosine kinase 1, previously recognized as a candidate tumor suppressor gene (TSG) for leukemia and other human malignancies.
|
21856257 |
2011 |
|
leukemia
|
0.050 |
Biomarker
|
disease |
BEFREE |
The DOK1 gene is a putative tumour suppressor gene located on the human chromosome 2p13 which is frequently rearranged in leukaemia and other human tumours.
|
21796618 |
2012 |
|
Childhood Leukemia
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Survival analyses showed that low-expressed DOK1/2 were associated with markedly shorter overall survival and leukemia free survival in both whole-cohort AML and non-M3 AML patients.
|
29150948 |
2018 |
|
Childhood Leukemia
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
The data in this report show that both the DOK1 and the DOK2 adaptor proteins are constitutively expressed in the myelomonoblastic leukemia cell line, HL-60, and that expression of both proteins is induced by the chemotherapeutic differentiation causing agents, all-trans retinoic acid (atRA) and 1,25-dihydroxyvitamin D3 (VD3).
|
16823827 |
2006 |
|
Childhood Leukemia
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
To assess the so far unknown role of DOK1 in colorectal cancer (CRC), we generated DOK1 mutants which mimic the domain structure and subcellular distribution of DOK1 protein variants in leukemia patients.
|
27428427 |
2016 |
|
Childhood Leukemia
|
0.040 |
Biomarker
|
disease |
BEFREE |
Among the genes identified, one of particular interest was DOK1, or downstream of tyrosine kinase 1, previously recognized as a candidate tumor suppressor gene (TSG) for leukemia and other human malignancies.
|
21856257 |
2011 |
|
Leukemogenesis
|
0.030 |
Biomarker
|
disease |
BEFREE |
This is the first example of a Dok1 mutation in B-CLL and the data suggest that Dok1 might play a role in leukemogenesis.
|
14730347 |
2004 |
|
Leukemogenesis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Originally identified in chronic myelogenous leukemia cells as a highly phosphorylated substrate for the chimeric p210(bcr-abl) protein, DOK1 was suspected to play a role in leukemogenesis.
|
16823827 |
2006 |
|
Leukemogenesis
|
0.030 |
Biomarker
|
disease |
BEFREE |
These data indicate that p62(dok) acts as a negative regulator of growth factor-induced cell proliferation, at least in part through downregulating Ras/MAPK signaling pathway, and that p62(dok) can oppose leukemogenesis by p210(bcr-abl).
|
11489947 |
2001 |
|
Burkitt Lymphoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Dok1 expression was down-regulated in all BL and XLP-LCL cell lines in comparison to the control cells.
|
16338067 |
2007 |
|
Burkitt Lymphoma
|
0.020 |
AlteredExpression
|
disease |
LHGDN |
Dok1 expression was down-regulated in all BL and XLP-LCL cell lines in comparison to the control cells.
|
16338067 |
2007 |
|
Burkitt Lymphoma
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
We further observed that DOK1 hypermethylation occurs frequently in a variety of primary human neoplasm including solid tumours (93% in HNC, 81% in lung cancer) and haematopoietic malignancy (64% in Burkitt's lymphoma).
|
21796618 |
2012 |
|
Chronic Lymphocytic Leukemia
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
We have screened the Dok1 gene for mutations from 46 individuals with B-CLL using heteroduplex analysis.
|
14730347 |
2004 |
|
Chronic Lymphocytic Leukemia
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Germline mutations in Dok1 do not predispose to chronic lymphocytic leukemia.
|
15541476 |
2005 |
|
Malignant neoplasm of stomach
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
Among differentially methylated genes, we identified new genes (CHRNA3 and DOK1) as targets of aberrant hypermethylation in GC, suggesting that epigenetic deregulation of these genes and their corresponding cellular pathways may promote the development and progression of GC.
|
21831520 |
2011 |
|
Malignant neoplasm of stomach
|
0.020 |
Biomarker
|
disease |
BEFREE |
Docking protein-1 promotes inflammatory macrophage signaling in gastric cancer.
|
31646096 |
2019 |
|
Adult Burkitt Lymphoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Dok1 expression was down-regulated in all BL and XLP-LCL cell lines in comparison to the control cells.
|
16338067 |
2007 |
|
Adult Burkitt Lymphoma
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
We further observed that DOK1 hypermethylation occurs frequently in a variety of primary human neoplasm including solid tumours (93% in HNC, 81% in lung cancer) and haematopoietic malignancy (64% in Burkitt's lymphoma).
|
21796618 |
2012 |
|
Childhood Burkitt Lymphoma
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
We further observed that DOK1 hypermethylation occurs frequently in a variety of primary human neoplasm including solid tumours (93% in HNC, 81% in lung cancer) and haematopoietic malignancy (64% in Burkitt's lymphoma).
|
21796618 |
2012 |